Galcanezumab

Galcanezumab is a monoclonal antibody designed for the prevention of migraine. It is developed and marketed by Eli Lilly and Company under the brand name Emgality.

Mechanism of Action

Galcanezumab works by binding to calcitonin gene-related peptide (CGRP) and blocking its binding to the receptor. CGRP is a neuropeptide that plays a crucial role in the pathophysiology of migraine.

Clinical Use

Galcanezumab is used for the preventive treatment of migraine in adults. It is administered once a month as a subcutaneous injection.

Side Effects

The most common side effects of galcanezumab include injection site reactions, such as pain, redness, and itching, and constipation.

Clinical Trials

Several clinical trials have demonstrated the efficacy and safety of galcanezumab in the prevention of migraine. These include the EVOLVE-1, EVOLVE-2, and REGAIN studies.

See Also

• Monoclonal antibodies
• Migraine
• Eli Lilly and Company
• Calcitonin gene-related peptide

References

Galcanezumab Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.

Translate to: East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski